相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer
Ahnah Song et al.
CLINICAL CANCER RESEARCH (2015)
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer
Ryohei Katayama et al.
CLINICAL CANCER RESEARCH (2015)
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
Tatsushi Kodama et al.
CANCER LETTERS (2014)
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib
Qinhua Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
Ted W. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
Thomas Wiesner et al.
NATURE COMMUNICATIONS (2014)
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
Luc Friboulet et al.
CANCER DISCOVERY (2014)
Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1
Shinji Yamazaki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas
Lynette M. Sholl et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches
Huiyong Sun et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2013)
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Justin F. Gainor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
ALK in Lung Cancer: Past, Present, and Future
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells
Mikko Taipale et al.
NATURE BIOTECHNOLOGY (2013)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Mark M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
Monika A. Davare et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types
Craig P. Giacomini et al.
PLOS GENETICS (2013)
SC-1, a sorafenib derivative, induces apoptosis in epidermal growth factor receptor wild type non-small cell lung cancer through the inhibition of signal transducers and activators of transcription 3
Cheng-Yi Wang et al.
CANCER RESEARCH (2012)
Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
Victoria M. Rimkunas et al.
CLINICAL CANCER RESEARCH (2012)
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2012)
ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
Sai-Hong Ignatius Ou et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
The transcriptional landscape and mutational profile of lung adenocarcinoma
Jeong-Sun Seo et al.
GENOME RESEARCH (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Ting-Lei Gu et al.
PLOS ONE (2011)
Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours
Ashley H. Birch et al.
PLOS ONE (2011)
A Cre/LoxP Conditional Luciferase Reporter Transgenic Mouse for Bioluminescence Monitoring of Tumorigenesis
Steve Woolfenden et al.
GENESIS (2009)
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Jeffrey A. Engelman et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice
Al Charest et al.
CANCER RESEARCH (2006)
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
AH Bild et al.
NATURE (2006)
Diversity of mechanism-based pharmacodynamic models
DE Mager et al.
DRUG METABOLISM AND DISPOSITION (2003)
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)
A Charest et al.
GENES CHROMOSOMES & CANCER (2003)
Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma
A Charest et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
A Bhattacharjee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Diversity of gene expression in adenocarcinoma of the lung
ME Garber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The protein tyrosine kinase family of the human genome
DR Robinson et al.
ONCOGENE (2000)
分享论文
